Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Abiraterone + Prednisone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 54 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02429193 | Phase II | Enzalutamide Abiraterone + Prednisone | Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) | Completed | CAN | 0 |
NCT04887506 | Phase III | Abiraterone + Prednisone Prednisone + TAVT-45 | TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer | Completed | USA | SWE | POL | HUN | GBR | FRA | ESP | 1 |
NCT03511196 | Phase I | Abiraterone + Prednisone Leuprolide Goserelin Triptorelin | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | Active, not recruiting | USA | 0 |
NCT03012321 | Phase II | Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib | Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | Active, not recruiting | USA | 0 |
NCT04497844 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) | Active, not recruiting | USA | TUR | SWE | POL | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 12 |
NCT01715285 | Phase III | Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) | Completed | TUR | SWE | SVK | ROU | POL | NZL | NLD | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 11 |
NCT04812366 | Phase II | Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) | Recruiting | USA | CAN | 0 |
NCT06320067 | Phase III | Darolutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Apalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + Docetaxel + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Darolutamide Abiraterone + Docetaxel + Prednisone Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Docetaxel + Niraparib and abiraterone acetate + Prednisolone Niraparib and abiraterone acetate + Prednisone Docetaxel + Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Apalutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Enzalutamide Apalutamide + Docetaxel Docetaxel + Enzalutamide Apalutamide Abiraterone + Prednisone Darolutamide + Docetaxel | A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2) | Recruiting | GBR | 0 |
NCT05288166 | Phase III | Abiraterone + Prednisone Abemaciclib + Abiraterone + Prednisone | A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 5 |
NCT04446117 | Phase III | Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT03419234 | Phase II | Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone | Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel | Active, not recruiting | USA | 1 |
NCT02218606 | Phase II | Cabazitaxel Abiraterone + Prednisone | Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | Completed | USA | 0 |
NCT03833921 | Phase II | Abiraterone + Prednisone | Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) | Recruiting | USA | 0 |
NCT04291664 | Phase I | Abiraterone + Prednisone DST-2970 + Prednisone | PK and Dose Escalation and Expansion Study of DST-2970 | Terminated | USA | 0 |
NCT04787744 | Phase II | Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) | Recruiting | USA | 0 |
NCT03706365 | Phase II | Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | Active, not recruiting | USA | ROU | NLD | FRA | ESP | DNK | DEU | AUS | 3 |
NCT04691804 | Phase III | Abiraterone + Fluzoparib + Prednisone Abiraterone + Prednisone | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | POL | HUN | GBR | FRA | ESP | CZE | BEL | AUS | 4 |
NCT03748641 | Phase III | Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 10 |
NCT04876651 | Phase III | Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | Recruiting | NZL | AUS | 0 |
NCT03649841 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy | Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer | Terminated | USA | 0 |
NCT03827473 | Phase II | Abiraterone + Prednisone Docetaxel | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) | Terminated | USA | 0 |
NCT04647526 | Phase III | Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) | Active, not recruiting | USA | SWE | NLD | GBR | FRA | CAN | 0 |
NCT03565835 | Phase II | Abiraterone + Prednisone | Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | Unknown status | USA | 0 |
NCT01576172 | Phase II | Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib | Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT06136650 | Phase III | Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide | A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Recruiting | USA | TUR | SWE | SVK | ROU | NZL | LVA | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | EST | ESP | DEU | CZE | BRA | AUS | 17 |
NCT01688492 | Phase Ib/II | Abiraterone + Prednisone Ipilimumab | Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04175431 | Phase II | Abiraterone + Prednisone | Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | Recruiting | USA | 0 |
NCT06520345 | Phase III | Abiraterone + Methylprednisolone Docetaxel + Prednisolone Abiraterone + Dexamethasone Docetaxel + Prednisone Abiraterone + Prednisone 177Lu-J591 + Docetaxel + Prednisone 177Lu-J591 + Enzalutamide + Prednisone 177Lu-J591 + Abiraterone + Methylprednisolone 177Lu-J591 + Abiraterone + Dexamethasone 177Lu-J591 + Docetaxel + Prednisolone Enzalutamide + Prednisolone Enzalutamide + Prednisone 177Lu-J591 + Enzalutamide + Prednisolone Abiraterone + Prednisolone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisolone | The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL) | Recruiting | USA | AUS | 0 |
NCT06378866 | Phase II | Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide | Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) | Recruiting | USA | 0 |
NCT05204927 | Phase III | Abiraterone + Enzalutamide lutetium Lu 177 vipivotide tetraxetan Abiraterone + Prednisone | Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | Active, not recruiting | USA | ITA | FRA | ESP | 0 |
NCT01940276 | Phase II | Abiraterone + Prednisone | Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer | Completed | USA | 0 |
NCT06496581 | Phase III | Enzalutamide Abiraterone + Docetaxel + Prednisone Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + Docetaxel + lutetium Lu 177 vipivotide tetraxetan + Prednisone Abiraterone + lutetium Lu 177 vipivotide tetraxetan + Prednisone Apalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel Abiraterone + Prednisone Apalutamide | Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | Not yet recruiting | FRA | 0 |
NCT03016741 | FDA approved | Enzalutamide Abiraterone + Prednisone | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | Unknown status | USA | 0 |
NCT06173362 | Phase II | Darolutamide Abiraterone + Prednisone | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT05276492 | Phase I | Abiraterone + Prednisone | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. | Active, not recruiting | USA | 0 |
NCT03834519 | Phase III | Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) | Completed | USA | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 5 |